The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes

Normal Population Clinical Trial

— cirrusOCT  

Official title:

The Performances of Spectral Domain Optical Coherence Tomography for Distinguishing Between Normal Eyes, Glaucoma Suspect and Glaucomatous Eyes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01067482
• Other study ID #: EC 52-336-02-1-2
• Status: Completed
• Phase: N/A
• First received: February 10, 2010
• Last updated: March 22, 2010
• Start date: September 2009
• Est. completion date: March 2010

Study information

• Verified date: October 2009
• Source: Prince of Songkla University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Ethical Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate performances of each parameters of spectral domain (Cirrus) optical coherence tomography for distinguishing between normal eyes, glaucoma suspect and glaucomatous eyes

Description:

Aim to determine which parameter of cirrus OCT is best sensitivity and specificity for glaucoma detection

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• BCVA at least 20/60

• refractive error +/- 5 D Or astig +/- 3 D

• enrolled in 3 population group (glaucoma, glaucoma suspect or normal)

Exclusion Criteria:

• VA less than 20/60

• marked RF error

• previous ocular trauma or surgery

• unreliable visual field

• poor signal cirrus OCT (less than 7)

• other causes of optic nerve or macular disease other than glaucoma

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma Patient
• Glaucoma Suspect Patient
• Macular Thickness by Location
• Normal Population
• Ocular Hypertension
• RNFL Thickness by Location

Locations

Country	Name	City	State
Thailand	Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University	Hat-yai,	Songkhla, Thailand.

Sponsors (1)

Lead Sponsor	Collaborator
Prince of Songkla University

Country where clinical trial is conducted

Thailand,